Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
出版年份 2021 全文链接
标题
Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-10
DOI
10.1186/s12933-021-01323-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
- (2021) Caiyun Zheng et al. Cardiovascular Diabetology
- Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
- (2020) Tobias Täger et al. HEART FAILURE REVIEWS
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study
- (2019) Anna Norhammar et al. DIABETES OBESITY & METABOLISM
- The Mediterranean Diet and Cardiovascular Health
- (2019) Miguel A. Martínez-González et al. CIRCULATION RESEARCH
- Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
- (2019) Binayak Sinha et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- A Traditional Mediterranean Diet Effectively Reduces Inflammation and Improves Cardiovascular Health
- (2019) Cristina Razquin et al. Nutrients
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
- (2019) Gian Paolo Fadini et al. Diabetes Therapy
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
- (2018) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
- (2018) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
- (2018) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
- (2017) Ovidiu Chioncel et al. EUROPEAN JOURNAL OF HEART FAILURE
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database
- (2017) Konstantinos A. Toulis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
- (2017) Jacob A. Udell et al. CIRCULATION
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
- (2016) Matteo Monami et al. ACTA DIABETOLOGICA
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores
- (2016) Samy Suissa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and DeathCLINICAL PERSPECTIVE
- (2015) Matthew A. Cavender et al. CIRCULATION
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) André J. Scheen CLINICAL PHARMACOKINETICS
- A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: Are individual components equal?
- (2015) Giuseppe Grosso et al. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
- Excess Mortality among Persons with Type 2 Diabetes
- (2015) Mauro Tancredi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
- (2015) Anoop Dinesh Shah et al. Lancet Diabetes & Endocrinology
- Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
- (2015) Deborah Hinnen Therapeutic Advances in Endocrinology and Metabolism
- Two-year outcome of patients after a first hospitalization for heart failure: A national observational study
- (2014) Philippe Tuppin et al. Archives of Cardiovascular Diseases
- Diabetes in Europe: An update
- (2013) T. Tamayo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Base de datos SIDIAP: la historia clínica informatizada de Atención Primaria como fuente de información para la investigación epidemiológica
- (2012) Bonaventura Bolíbar et al. MEDICINA CLINICA
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA)
- (2008) M. Felícitas Domínguez-Berjón et al. Gaceta Sanitaria
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search